MannKind Corp (MNKD):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:MannKind Corp (MNKD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9982
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a US FDA approved rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. The company develops products based on its proprietary Technosphere formulation technology. It has manufacturing facility in Danbury, Connecticut and sells its product through wholesale distributors and specialty pharmacies. MannKind is headquartered in California, the US.

MannKind Corp (MNKD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MannKind Corp, Medical Devices Deals, 2012 to YTD 2018 10
MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MannKind Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
MannKind Enters into Distribution Agreement with Tanner Pharma 12
MannKind to Enter into Marketing and Distribution Agreement with Cipla 13
MannKind and Biomm Enter into Distribution Agreement 14
MannKind Partners with JDRF 15
Licensing Agreements 16
United Therapeutics Enters into Licensing Agreement with MannKind 16
Receptor Life Sciences Enters into Licensing Agreement with MannKind 17
Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 18
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 20
Equity Offering 21
MannKind Raises USD28 Million in Private Placement of Shares 21
Mannkind to Raise USD61 Million in Private Placement of Shares 23
MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 25
MannKind Raises USD36.2 Million in Private Placement of Shares 26
Mannkind Raises USD50 Million in Private Placment of Shares 27
MannKind Announces Public Offering Of Common Stock For US$50 Million 29
MannKind Completes Public Offering Of Common Stock And Warrants For US$92 Million 30
MannKind Completes Public Offering Of Units For US$86 Million 32
Debt Offering 34
MannKind Completes First Tranche Of Private Placement Of Notes For US$40 Million 34
MannKind Corp – Key Competitors 36
MannKind Corp – Key Employees 37
MannKind Corp – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Strategy And Business Planning 39
Sep 05, 2018: MannKind and United Therapeutics to advance dry powder treprostinil 39
Financial Announcements 40
Nov 01, 2018: MannKind reports 2018 third quarter financial results 40
Aug 02, 2018: MannKind Reports 2018 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET 42
May 09, 2018: MannKind Reports 2018 First Quarter Financial Results 44
Feb 27, 2018: MannKind Reports 2017 Fourth Quarter and Full Year Financial Results 45
Nov 07, 2017: MannKind Reports 2017 Third Quarter Financial Results 47
Aug 07, 2017: MannKind Reports 2017 Second Quarter Financial Results 49
May 10, 2017: MannKind Reports 2017 First Quarter Financial Results 51
Mar 16, 2017: MannKind Reports 2016 Fourth Quarter and Full Year Financial Results 52
Corporate Communications 53
Jun 25, 2018: MannKind Set to Join Russell 3000 Index 53
Feb 06, 2018: MannKind Names David Kendall As Chief Medical Officer 54
Jul 17, 2017: Steven Binder Joins MannKind as Chief Financial Officer 55
Jul 12, 2017: Patrick McCauley Joins MannKind as Chief Commercial Officer 56
Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks 57
Product News 58
08/17/2018: NUI Galway finds new treatment strategy for breast cancer relapse 58
Mar 08, 2017: MannKind and Charles Mattocks Announce “REVERSED”-America’s First Docu-Series Tackling Diabetes 59
02/01/2017: MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza Growth 60
Other Significant Developments 61
Jan 09, 2017: MannKind Receives $30.6 Million From Sanofi 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
MannKind Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MannKind Corp, Deals By Therapy Area, 2012 to YTD 2018 9
MannKind Corp, Medical Devices Deals, 2012 to YTD 2018 10
MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MannKind Enters into Distribution Agreement with Tanner Pharma 12
MannKind to Enter into Marketing and Distribution Agreement with Cipla 13
MannKind and Biomm Enter into Distribution Agreement 14
MannKind Partners with JDRF 15
United Therapeutics Enters into Licensing Agreement with MannKind 16
Receptor Life Sciences Enters into Licensing Agreement with MannKind 17
Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 18
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 20
MannKind Raises USD28 Million in Private Placement of Shares 21
Mannkind to Raise USD61 Million in Private Placement of Shares 23
MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 25
MannKind Raises USD36.2 Million in Private Placement of Shares 26
Mannkind Raises USD50 Million in Private Placment of Shares 27
MannKind Announces Public Offering Of Common Stock For US$50 Million 29
MannKind Completes Public Offering Of Common Stock And Warrants For US$92 Million 30
MannKind Completes Public Offering Of Units For US$86 Million 32
MannKind Completes First Tranche Of Private Placement Of Notes For US$40 Million 34
MannKind Corp, Key Competitors 36
MannKind Corp, Key Employees 37
MannKind Corp, Other Locations 38
MannKind Corp, Subsidiaries 38

List of Figures
MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MannKind Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[MannKind Corp (MNKD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Hartford Financial Services Group, Inc.:企業のM&A・事業提携・投資動向
    The Hartford Financial Services Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Hartford Financial Services Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • PerkinElmer Inc (PKI):企業の財務・戦略的SWOT分析
    PerkinElmer Inc (PKI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Krispy Kreme Doughnuts, Inc.:企業の戦略的SWOT分析
    Krispy Kreme Doughnuts, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Chico’s FAS Inc:戦略・SWOT・企業財務分析
    Chico's FAS Inc - Strategy, SWOT and Corporate Finance Report Summary Chico's FAS Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • IDOX Plc (IDOX):企業の財務・戦略的SWOT分析
    Summary IDOX Plc (IDOX) is an information technology company that supplies and develops software solutions and information services. The company offers services such as funding, manages services, government and compliance solutions. Its government services include environmental, legal, democratic, e …
  • Merafe Resources Ltd
    Merafe Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Merafe Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • The Williams Companies Inc (WMB):企業の財務・戦略的SWOT分析
    The Williams Companies Inc (WMB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Seaboard Corporation:企業の戦略・SWOT・財務情報
    Seaboard Corporation - Strategy, SWOT and Corporate Finance Report Summary Seaboard Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Tsakos Energy Navigation Limited:企業の戦略・SWOT・財務分析
    Tsakos Energy Navigation Limited - Strategy, SWOT and Corporate Finance Report Summary Tsakos Energy Navigation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Furukawa Electric Co Ltd (FUWAY):企業の財務・戦略的SWOT分析
    Furukawa Electric Co Ltd (FUWAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Siemens Ltd (SIEMENS):企業の財務・戦略的SWOT分析
    Siemens Ltd (SIEMENS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Clean Harbors Inc (CLH):石油・ガス:M&Aディール及び事業提携情報
    Summary Clean Harbors Inc (Clean Harbors) is a provider of environmental, industrial and energy services. The company offers waste disposal and recycling, emergency response, chemical packing, field services, production services, exploration services, directional boring, lodging services and onsite …
  • Vivimed Labs Ltd (VIVIMEDLAB):企業の財務・戦略的SWOT分析
    Vivimed Labs Ltd (VIVIMEDLAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Generex Biotechnology Corp (GNBT):製薬・医療:M&Aディール及び事業提携情報
    Summary Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulatio …
  • Nachi-Fujikoshi Corp (6474):企業の財務・戦略的SWOT分析
    Nachi-Fujikoshi Corp (6474) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Petroleum Development Oman LLC:企業の戦略的SWOT分析
    Petroleum Development Oman LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Clean Energy Finance Corp:電力:M&Aディール及び事業提携情報
    Summary Clean Energy Finance Corp (CEFC) is a statutory authority that provides investments for clean energy projects including renewable energy, energy efficiency and low emissions technologies. The authority financing structures include project finance, climate bonds and equity funds, aggregation …
  • Reliance Infrastructure Ltd (RELINFRA):企業の財務・戦略的SWOT分析
    Reliance Infrastructure Ltd (RELINFRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Amara Raja Batteries Ltd (AMARAJABAT):企業の財務・戦略的SWOT分析
    Summary Amara Raja Batteries Ltd (Amara Raja) is a manufacturer of lead-acid storage batteries. The company operates through two divisions such as automotive battery and industrial battery division. Its automotive battery division offers two-wheeler batteries, four-wheeler batteries and tubular batt …
  • TriVascular Inc:製品パイプライン分析
    Summary TriVascular Inc (TriVascular), a subsidiary of Endologix Inc is a medical device company that researches, designs and manufactures technologies to provide optimal solutions for endovascular aortic repair. The company’s product comprise endovascular grafts and self-expanding stent grafts; ova …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆